Phase III Success For Roche’s Crovalimab In Crowded PNH Market

But AstraZeneca Expected To Retain Grip In The Space

 
• By Andrew McConaghie
  
Roche_Logo_Glass
Roche expects to file crovalimab shortly and expects a US FDA approval by late 2023/ early 2024.

More from Clinical Trials

More from R&D